Omiganan Pentahydrochloride

Omiganan Pentahydrochloride (MBI 226), a Topical 12-Amino-Acid Cationic Peptide, has good antimicrobial activity and bactericidal activity.

Designed for biological research and industrial applications, not intended for individual clinical or medical purposes.
Omiganan Pentahydrochloride(CAS 269062-93-3)

CAT No: 10-101-93

CAS No:269062-93-3

Synonyms/Alias:Omiganan pentahydrochloride;269062-93-3;MBI 226;MBI-226;Omiganan (pentahydrochloride);626233-83-8;Omiganan HCl;UNII-LX2P9RD54V;Omiganan pentahydrochloride [USAN];LX2P9RD54V;CHEMBL1793889;EX-A7464;Cevidoplenib dimesylate hydrochloride;AT42482;HY-105048A;TS-10053;CS-0024803;L-Isoleucyl-L-leucyl-L-arginyl-L-tryptophyl-L-prolyl-L-tryptophyl-L-tryptophyl-L-prolyl-L-tryptophyl-L-arginyl-L-arginyl-L-lysinamide pentahydrochloride;L-Lysinamide, L-isoleucyl-L-leucyl-L-arginyl-L-tryptophyl-L-prolyl-L-tryptophyl-L-tryptophyl-L-prolyl-L-tryptophyl-L-arginyl-L-arginyl-, hydrochloride (1:5);L-Lysinamide, L-isoleucyl-L-leucyl-L-arginyl-L-tryptophyl-L-prolyl-L-tryptophyl-L-tryptophyl-L-prolyl-L-tryptophyl-L-arginyl-L-arginyl-, pentahydrochloride;

Custom Peptide Synthesis
cGMP Peptide
  • Registration of APIs
  • CMC information required for an IND
  • IND and NDA support
  • Drug master files (DMF) filing
M.F/Formula
C90H132Cl5N27O12
M.W/Mr.
1961.4
Sequence
One Letter Code:ILRWPWWPWRRK
Three Letter Code:H-Ile-Leu-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Arg-Arg-Lys-NH2.5HCl
Labeling Target
Bacterial
Application
Omiganan pentahydrochloride, a bactericidal and fungicidal cationic peptide being developed as a topical gel for prevention of catheter-associated infections, inhibited commonly occurring fungal pathogens.
Appearance
White powder
Purity
Purity (HPLC) ≥98.0%
Biological Activity
Omiganan pentahydrochloride is a cationic peptide with antibacterial activity.
Areas of Interest
Infection
Target
Antimicrobial
Source#
Synthetic
Solubility
−20°C
InChI
InChI=1S/C90H127N27O12.5ClH/c1-5-51(4)75(92)85(127)113-68(41-50(2)3)80(122)109-67(32-18-38-102-90(98)99)79(121)114-71(44-54-48-105-62-27-12-8-23-58(54)62)86(128)116-39-19-34-74(116)84(126)112-70(43-53-47-104-61-26-11-7-22-57(53)61)82(124)115-72(45-55-49-106-63-28-13-9-24-59(55)63)87(129)117-40-20-33-73(117)83(125)111-69(42-52-46-103-60-25-10-6-21-56(52)60)81(123)110-66(31-17-37-101-89(96)97)78(120)108-65(30-16-36-100-88(94)95)77(119)107-64(76(93)118)29-14-15-35-91;;;;;/h6-13,21-28,46-51,64-75,103-106H,5,14-20,29-45,91-92H2,1-4H3,(H2,93,118)(H,107,119)(H,108,120)(H,109,122)(H,110,123)(H,111,125)(H,112,126)(H,113,127)(H,114,121)(H,115,124)(H4,94,95,100)(H4,96,97,101)(H4,98,99,102);5*1H/t51-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-;;;;;/m0...../s1
InChI Key
WTNSIKUBZJCPLJ-IQOWARLESA-N
BoilingPoint
N/A
References

The activity of omiganan pentahydrochloride (formerly MBI 226; a synthetic cationic peptide) was assessed against 1,437 recent clinical bacterial isolates and 214 recent clinical yeast isolates. The omiganan was highly active, and minimal bactericidal concentrations or minimal fungicidal concentrations were either equal to or two- to fourfold higher than MICs. Kill curve experiments showed a clear pattern of bactericidal activity.

Sader, H. S., Fedler, K. A., Rennie, R. P., Stevens, S., & Jones, R. N. (2004). Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity. Antimicrobial agents and chemotherapy, 48(8), 3112-3118.

Omiganan pentahydrochloride is a cidal cationic peptide with a broad antimicrobial spectrum, including yeast, currently in development as a topical agent for the prevention of catheter-associated infections. We evaluated the spectrum and potency of omiganan against pathogens commonly associated with such infections.

Fritsche, T. R., Rhomberg, P. R., Sader, H. S., & Jones, R. N. (2008). Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections. Journal of antimicrobial chemotherapy.

Ribosomally synthesized antimicrobial peptides have very wide killing spectra and bacterial resistance to these peptides seems to be a rare phenomenon. Indolicidin is a ribosomally synthesized antimicrobial peptide that served as a template to omiganan, which is in development for the prevention of catheter-related bloodstream infections; clinical trials also proved its efficiency against acne vulgaris. Omiganan is the most advanced molecule in the front line of clinical applications of antimicrobial peptides. The mode and site of action of omiganan are not yet settled although its interaction with membranes is known to play a fundamental role. The biochemical and biophysical foundations for the action of indolicidin and its analogues are reviewed in this paper, as well as the clinical application of omiganan. The in vitro efficiency tests and the outcome of clinical trials are addressed. Altogether, despite the very specific use of omiganan as a topical antibiotic, it has the potential of being a pioneer of a new generation of antibiotics that carry the promise of ending the multi-resistance problem.

Melo, M. N., Dugourd, D., & Castanho, M. A. (2006). Omiganan pentahydrochloride in the front line of clinical applications of antimicrobial peptides. Recent patents on anti-infective drug discovery, 1(2), 201-207.

Melting Point
N/A

Useful Tools

Peptide Calculator

Abbreviation List

Peptide Glossary

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Featured Services
Custom Conjugation ServicePeptide Analysis ServicesPeptide Modification ServicesPeptide CDMOPeptide Synthesis ServicesEpitope Mapping ServicesPeptide Nucleic Acids SynthesiscGMP Peptide Service
Hot Products
About us

Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.

From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.

Our Customers